Skip to content
All Digests

Vulvar & Vaginal Cancer Digest

This Month in Vaginal & Vulvar Cancer Research

This Month in Vaginal Cancer Research

July 2026

Vaginal cancer is one of the rarest gynecologic cancers, accounting for only about 1-3% of gynecologic cancer diagnoses, so its research tends to arrive in small, meaningful increments rather than large waves, and July 2026 followed that pattern. The strongest thread this month was treatment for the precancer stage: long-term data from a single center showed that internal radiation can control stubborn, recurring high-grade vaginal precancer with very few side effects. Alongside it came some of the first focused evidence on immunotherapy for advanced vulvar and vaginal cancer, a growing argument that vaginal melanoma should be understood as its own distinct disease rather than lumped in with vulvar melanoma, and practical guidance on living well after treatment, including new expert consensus that menopausal hormone therapy can be considered for carefully selected vaginal cancer survivors. Population data from Estonia rounded out the month with an encouraging signal: five-year survival for vaginal cancer there has risen substantially over the past few decades. Taken together, it was a quiet but genuinely constructive month, with progress spread across prevention, treatment, and survivorship.

 

The papers highlighted here represent a selection of those published during the month. The papers were selected and summarized by AI. Accuracy of the summaries was confirmed by a scientist. This digest incorporates only open-access research articles that are free to be read by the entire community and that are explicitly licensed to be shared and reused.

A less-invasive radiation option is helping treat stubborn vaginal precancer

Before vaginal cancer develops, many people are diagnosed with vaginal intraepithelial neoplasia, or VaIN, abnormal cell changes in the vaginal lining that can, if untreated, progress to cancer. High-grade VaIN often comes back after treatment, and each round of surgery takes a toll, so gentler options that still work matter a great deal.

  • For people whose high-grade VaIN keeps returning despite multiple prior treatments, internal radiation offered excellent control with very few side effects in a long-term study from a single hospital in Turin, Italy. Researchers reviewed 31 patients treated with high-dose-rate vaginal brachytherapy (a form of internal radiation in which a radioactive source is placed directly inside the vagina for a short time) between 1997 and 2024. After a median follow-up of nearly four years, 96.8% had their disease controlled locally, none progressed to invasive cancer, and serious side effects were rare (a single severe event across the whole group). Because this is a look back at one center's experience rather than a clinical trial, it can't prove brachytherapy is better than other options, but it's encouraging evidence that a less-invasive approach can help when repeated surgeries have not. (Read the full paper)

Additional citations on this topic: Yao XQ, et al. "[Clinical efficacy of high-frequency electromagnetic wave (radiofrequency) therapy for high-grade vaginal intraepithelial neoplasia]." Zhonghua Yi Xue Za Zhi. https://doi.org/10.3760/cma.j.cn112137-20260401-00886 (subscription access)

Immunotherapy shows modest but real activity in advanced vulvar and vaginal cancers

When these cancers come back or spread, treatment choices have historically been borrowed from other cancers because dedicated studies are so scarce. This month brought some of the first focused evidence on immunotherapy (treatment that helps your own immune system recognize and attack cancer) in this exact setting.

  • Immune checkpoint inhibitors (drugs such as pembrolizumab that release a natural "brake" on immune cells so they can attack tumor cells) produced meaningful, lasting benefit for a minority of patients with recurrent vulvar and vaginal carcinoma in a single-center study of 21 people treated between 2016 and 2025. About 29% of those whose response could be measured saw their tumors shrink, and among responders the benefit lasted a median of 14 months, but overall survival was short (a median of about 4.6 months), reflecting how advanced and hard-to-treat this disease is by the time it recurs. Serious immune-related side effects occurred in roughly 1 in 5 patients. This is a small, retrospective look, so the numbers should be read as a signal rather than a promise, but it suggests immunotherapy is a reasonable option to discuss for select patients — especially those whose tumors carry the PD-L1 marker, which most in this group did. (Read the full paper)

Vaginal melanoma is being recognized as its own distinct disease, and that matters for treatment

Melanoma is best known as a skin cancer, but it can also arise in the vaginal lining, where it is called mucosal melanoma. It is rare and aggressive, and this month two open-access papers pushed toward diagnosing and understanding it more precisely.

  • A review argued that vaginal melanoma and vulvar melanoma, often lumped together as "vulvovaginal melanoma", should be treated as separate diseases, because they behave differently. Vulvar melanoma can partly resemble skin (cutaneous) melanoma, while vaginal melanoma more consistently behaves like mucosal melanoma, tends to be found at a later stage, and carries a poorer outlook. The authors make the case that research and treatment decisions should be "site-aware" rather than assuming the two are interchangeable, which is a distinction that could eventually shape which therapies are chosen. (Read the full paper)
  • A separate case report described using a combination of advanced ultrasound techniques, including 3D ultrasound, blood-flow imaging, elastography (which measures tissue stiffness), and contrast-enhanced ultrasound, to evaluate a primary vaginal melanoma before surgery in a 48-year-old woman. The imaging strongly suggested cancer, which biopsy confirmed. As a single case, it can't tell us how well this approach works in general, but it illustrates a potentially useful, lower-cost way to assess these tumors when MRI is limited. (Read the full paper)

Additional citations on this topic:

Life after treatment: better information and safer menopause care

For a cancer this rare, the experience of getting a diagnosis and living well afterward can feel isolating. Two open-access papers this month focused on those human dimensions.

  • People with vaginal and vulvar cancer often don't get the information they need, when they need it, according to an Australian study that combined questionnaires from 39 women with in-depth interviews. Satisfaction with information improved from before diagnosis through treatment, but at every stage about three-quarters of participants still reported at least one significant unmet information need. Doctors, internet searches, and family and friends were the most valued information sources, and the study translated participants' own words into 17 concrete recommendations for improving how information is shared across the care pathway. (Read the full paper)
  • Managing menopausal symptoms after cancer treatment is a common, under-served struggle, and a position paper from the International Federation of Gynecology and Obstetrics (FIGO) offered guidance that speaks directly to vaginal cancer survivors. Because vaginal cancer is generally not hormone-driven, the authors conclude that carefully selected survivors may be able to use systemic menopausal hormone therapy (MHT), which is a treatment that replaces estrogen to ease hot flashes, sleep problems, and genitourinary syndrome of menopause (vaginal dryness, discomfort, and urinary symptoms caused by low estrogen). Local vaginal hormones and non-hormonal options remain important too. This is expert consensus rather than a new trial, but it gives survivors and their doctors a clearer, evidence-based framework for a decision that often gets avoided out of caution. (Read the full paper)

The bigger picture: HPV is the common thread, and vaginal cancer survival is improving

Most vaginal cancers are linked to the human papillomavirus (HPV), the same virus behind most cervical cancers, which is why prevention and long-term population tracking matter for this community.

  • Survival for vaginal cancer is getting better, according to a population-based registry study covering all of Estonia from 1995 to 2022. Among the eight HPV-related cancer sites examined, five-year relative survival for vaginal cancer in women improved substantially from 45% to 73% over the study period. The study also documented a broader shift in HPV-related cancers away from the cervix (where screening and, increasingly, vaccination are working) toward other sites, underscoring that HPV prevention benefits reach well beyond cervical cancer alone. (Read the full paper)

Additional citations on this topic:

What Does This Mean for Me?

If you're living with high-grade VaIN that keeps coming back, know that repeated surgery isn't the only path. Internal radiation (brachytherapy) achieved very high control rates with minimal side effects in people who had already been through multiple treatments. A good question for your gynecologic oncologist: "Given how many treatments I've had, would vaginal brachytherapy be a reasonable option for me, and what would the side effects likely be?"

If you have advanced or recurrent vaginal (or vulvar) cancer, immunotherapy is worth asking about. It helped a minority of patients meaningfully in this month's study, and responses that did occur often lasted many months. Ask your care team whether your tumor has been tested for the PD-L1 marker, whether an immune checkpoint inhibitor might fit your situation, and whether a clinical trial is open to you. Trials are often where people with rare cancers gain access to newer options.

If you're a survivor navigating menopausal symptoms, you may have more options than you've been told. Because vaginal cancer is generally not hormone-driven, expert guidance now supports considering menopausal hormone therapy for carefully selected survivors, alongside local and non-hormonal treatments. It's worth a frank conversation with your care team about what's safe and appropriate for you rather than simply going without relief.

This digest is prepared by OCRA (Ovarian Cancer Research Alliance) for patients, caregivers, and advocates. It is intended to inform, not to guide individual treatment decisions. Please speak with your care team about what research findings may mean for your specific situation.

Sources

Directly Referenced in This Digest

  1. Di Muzio J, et al. "High-dose-rate vaginal brachytherapy for treatment of recurrent high-grade vaginal intraepithelial neoplasia." La Radiologia Medica. July 2026; 131(7):1261-1268. PMID 41915370. https://doi.org/10.1007/s11547-026-02208-x
  2. Abdeen CS, et al. "Beyond extrapolation: Immunotherapy outcomes in recurrent vulvovaginal carcinoma." Gynecologic Oncology. July 2026; 210:72-76. PMID 42202684. https://doi.org/10.1016/j.ygyno.2026.05.014
  3. Xu F. "Vulvar malignant melanoma versus vaginal malignant melanoma: distinct biology, distinct clinical behavior, and distinct management?" Frontiers in Oncology. July 23, 2026; 16:1907495. PMID 42563937. https://doi.org/10.3389/fonc.2026.1907495
  4. Qin HC, et al. "Multimodal ultrasound imaging in the diagnosis of primary vaginal malignant melanoma: A case report." Medicine (Baltimore). July 3, 2026; 105(27):e49636. PMID 42410847. https://doi.org/10.1097/MD.0000000000049636
  5. DiSipio T, et al. "Vaginal and vulvar cancer patient experiences of the information pathway from pre-diagnosis to treatment." Supportive Care in Cancer. July 21, 2026; 34(8). PMID 42481795. https://doi.org/10.1007/s00520-026-11022-0
  6. da Silva-Filho AL, et al. "Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age." International Journal of Gynaecology and Obstetrics. July 22, 2026. PMID 42483786. https://doi.org/10.1002/ijgo.71188
  7. Kase S, et al. "Changing burden of cancers related to human papillomavirus in Estonia: a population-based registry study." Acta Oncologica. July 27, 2026; 65:632-640. PMID 42504768. https://doi.org/10.2340/1651-226X.2026.45671

Additional Citations on Related Topics

These papers were published this month on vaginal cancer or a closely related topic but are not summarized above because they are behind subscription access or a restricted license. They are listed so researchers and community members can find them.

  1. Yao XQ, et al. "[Clinical efficacy of high-frequency electromagnetic wave (radiofrequency) therapy for high-grade vaginal intraepithelial neoplasia]." Zhonghua Yi Xue Za Zhi. July 21, 2026; 106(26):2744-2747. PMID 42477945. https://doi.org/10.3760/cma.j.cn112137-20260401-00886 (subscription access)
  2. Asher N, et al. "Vulvar and Vaginal Melanoma: Real-world Clinical Outcomes and Prognostic Differences From a Single-center Experience." Journal of Lower Genital Tract Disease. July 1, 2026; 30(3):252-258. PMID 42044311. https://doi.org/10.1097/LGT.0000000000000959 (subscription access)
  3. Persy H, et al. "Primary Vaginal Melanoma." International Journal of Gynecological Cancer. July 2026; 36(7):104646. PMID 41935874. https://doi.org/10.1016/j.ijgc.2026.104646 (subscription access)
  4. Yeung MCF, et al. "Integrated Clinicopathological and Multiomic Profiling Reveals MEIS1-rearranged Sarcoma as a Distinct Entity with Two Prognostic Subgroups." Modern Pathology. July 18, 2026; 101041. PMID 42471200. https://doi.org/10.1016/j.modpat.2026.101041 (restricted license, CC BY-NC-ND)
  5. Peng C, et al. "Multimodal Ultrasound in Evaluating Radiotherapy Efficacy for Vaginal Squamous Cell Carcinoma: A Case Report." Current Medical Imaging. July 7, 2026. PMID 42439341. https://doi.org/10.2174/0115734056465978260626093538 (subscription access)
  6. Ersoy E, et al. "Evaluating the cost-effectiveness of implementing HPV vaccination in Turkiye's National Immunization Program using the PRIME model." Ginekologia Polska. July 17, 2026. PMID 42464849. https://doi.org/10.5603/gpl.104730 (restricted license, CC BY-NC-ND)
  7. Talib G, et al. "HPV Prevalence Among Inuit Women in Northern Quebec, Canada: A Pre- and Post-Vaccination Analysis." Journal of Lower Genital Tract Disease. July 1, 2026; 30(3):194-198. PMID 41985196. https://doi.org/10.1097/LGT.0000000000000953 (restricted license, CC BY-NC-ND)
  8. Sharma S, et al. "Human Papillomavirus (HPV) — The Interplay between Vaginal Microbiota and HPV, along with its Prevention." Current HIV Research. July 2, 2026. PMID 42405387. https://doi.org/10.2174/011570162X461254260618050011 (subscription access)
  9. Gouveia MC, et al. "Single-dose human papillomavirus vaccination in Brazil: early coverage gains and randomized validation." International Journal of Gynecological Cancer. July 2026; 36(7):104478. PMID 41644382. https://doi.org/10.1016/j.ijgc.2026.104478 (subscription access)

This Month in Vulvar Cancer Research

July 2026

Vulvar cancer is rare, making up only a small fraction of gynecologic cancer diagnoses, and in most months the research reflects that, arriving in modest numbers and clustering around a few recurring questions. July 2026 followed that pattern, with the clearest new findings concentrated in three areas: how imaging is used to stage the disease, how rare vulvar cancers and unusual lesions are recognized and told apart from harmless look-alikes, and the early search for molecular targets that might one day guide treatment. Alongside these, the month also saw work on vulvar surgery and its lasting effects, on precancerous changes and the risk of recurrence, on survivorship and quality of life, and on disparities in who gets timely care. Taken together, it was a quieter month for practice-changing results but a steady one for the groundwork that shapes future care.

 

The papers highlighted here represent a selection of those published during the month. The papers were selected and summarized by AI. Accuracy of the summaries was confirmed by a scientist. This digest incorporates only open-access research articles that are free to be read by the entire community and that are explicitly licensed to be shared and reused.

Imaging is being refined to stage vulvar cancer more precisely, but it doesn't replace surgical checking of the lymph nodes

Knowing whether and how far a cancer has spread shapes almost every treatment decision, and imaging is central to answering that question before treatment begins.

  • For people facing locally advanced vulvar cancer, a scan called PET/CT can help map where the disease has spread and guide the treatment plan, but it has clear limits, and it cannot substitute for surgically testing the lymph nodes in the groin. A research team reviewed the published evidence on PET/CT (positron emission tomography combined with CT, an imaging test that highlights areas of high metabolic activity such as tumors) in vulvar cancer. They found it is most valuable for staging more advanced disease and for spotting spread to distant sites, and that it can help plan radiation therapy, but that it can miss very small deposits of cancer, and that MRI remains better for seeing the local extent of a tumor. Importantly, the authors emphasize that PET/CT does not replace sentinel lymph node biopsy (a procedure that identifies and tests the first one or two lymph nodes most likely to receive cancer cells from a tumor, sparing many patients more extensive groin surgery) for checking the groin. This was a review of existing studies rather than new trial data, so it summarizes current practice rather than changing it. (Read the full paper)

Additional citations on this topic:

Some vulvar cancers are easily mistaken for harmless skin problems, and getting to the right diagnosis can take too long

The vulva is affected by a wide range of conditions, and cancers or unusual growths that resemble common rashes or moles can go unrecognized for months. Research this month speaks to the challenge of telling the ordinary apart from the concerning.

  • A persistent vulvar itch or red patch that doesn't clear with the usual creams deserves a closer look, sometimes a biopsy, because it can occasionally be a rare cancer. A case report described a 58-year-old woman who had more than a year of vulvar itching and a red lesion that hadn't responded to antifungal and steroid treatments before a biopsy revealed extramammary Paget disease, an uncommon cancer that begins in the gland-related cells of the vulvar skin. Even though the biopsy suggested the disease was confined to the surface, her care team chose more extensive surgery out of concern that deeper invasion might be hiding; the final analysis confirmed the disease had not invaded and had been fully removed, with no recurrence at six months. As a single case report, this illustrates a pattern rather than proving a rule, but the pattern it illustrates, a long delay because the condition mimicked a benign skin problem, is a well-recognized issue with this rare cancer and a reminder to take persistent, treatment-resistant vulvar symptoms seriously. (Read the full paper)
  • Most pigmented spots (moles) in the genital area are benign, and a specialized skin-surface examination can help doctors feel confident about that without resorting to unnecessary surgery while staying alert for the rare mole that could be melanoma. Dermatologists reviewed 43 people with biopsy-confirmed benign genital moles, most of them on the vulva, and described two characteristic patterns seen under a dermatoscope (a magnifying tool that lets clinicians examine the surface and pigment patterns of a skin lesion). Recognizing these reassuring patterns, the authors note, can support more confident assessment of genital pigmented lesions, while attention to warning features helps flag the uncommon lesion that needs further testing. This is an observational diagnostic study; its relevance to this community lies in what it says about recognizing, and not over-treating, the pigmented lesions that turn out to be harmless. (Read the full paper)

Additional citations on this topic:

  • Senda Y, et al. "A Rare Case of Extramammary Paget Disease With Concurrent Herpes Simplex Virus Infection: Three-Color Immunohistochemical Analysis for Re-Evaluating Previous Hypotheses." Pathology International. July 2026. PMID 42402155. https://doi.org/10.1111/pin.70146 (subscription access)
  • Asher N, et al. "Vulvar and Vaginal Melanoma: Real-world Clinical Outcomes and Prognostic Differences From a Single-center Experience." Journal of Lower Genital Tract Disease. July 1, 2026. PMID 42044311. https://doi.org/10.1097/LGT.0000000000000959 (subscription access)

Researchers are searching for molecular targets that could open new treatment doors in vulvar cancer, but it's early

Most vulvar cancers are squamous cell carcinomas, and options for advanced disease remain limited, so scientists are looking for molecular features that might be matched to targeted drugs.

  • A pooled analysis suggests that HER2 (a protein that, when overactive, can drive some cancers and can be attacked by HER2-directed drugs) is only rarely present at high levels in vulvar squamous cell carcinoma, which tempers hopes that HER2-targeted therapy will help many people based on current data. Researchers combined nine earlier studies covering 769 patients and found that, using the strict testing criteria borrowed from breast cancer, only about 2% of vulvar cancers were HER2-positive (with a higher and less certain figure when looser criteria were used). The interest comes from a newer HER2-directed drug, trastuzumab deruxtecan (an antibody-drug conjugate, meaning an antibody that homes in on HER2 and carries a chemotherapy payload directly to cancer cells) which has shown activity across several HER2-expressing solid tumors. The authors conclude that HER2-positive vulvar cancer appears uncommon and that standardized testing is needed before its role can be judged. This is exploratory, hypothesis-generating research, not a practice change. It's worth noting that vulvar squamous cell carcinoma arises through two distinct biological routes: one linked to HPV (human papillomavirus) infection and one linked to chronic skin conditions such as lichen sclerosus, a condition that thins and scars vulvar tissue and can raise long-term cancer risk. The studies pooled here included a mix of both, part of why the results varied so much. (Read the full paper)

Additional citations on this topic:

  • Warmbold J, et al. "Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) by Tiplaxtinin Attenuates the Aggressive Phenotype of Vulvar Squamous Cell Carcinoma Cells." In Vivo. July–August 2026. PMID 42379802. https://doi.org/10.21873/invivo.14345 (subscription access)

Surgery is evolving to control the cancer while preserving function and reducing lasting harm

Surgery is the backbone of treatment for most vulvar cancers, and much of the field's effort goes toward achieving that while limiting the wound complications, lymphedema (long-term swelling of the leg or groin caused by damage to the lymphatic system during surgery), and effects on sexual function that can follow. Several papers this month address surgical technique and complication prevention; they are listed here for readers who wish to seek them out.

Additional citations on this topic:

  • Kjölhede K, et al. "Treatment patterns and outcomes in perineal primary vulvar cancer—a population-based Swedish cohort study." Acta Obstetricia et Gynecologica Scandinavica. July 22, 2026. PMID 42483828. https://doi.org/10.1111/aogs.70315 (open access; license unverified)
  • Ten Eikelder M, et al. "Clitoral reconstructive surgery for patients with vulvar carcinoma." Gynecologic Oncology. July 21, 2026. PMID 42480492. https://doi.org/10.1016/j.ygyno.2026.07.013 (subscription access)
  • Haidopoulos D, et al. "European Society of Gynaecological Oncology Consensus Statement on the prevention of surgical complications in gynecologic oncology." International Journal of Gynecological Cancer. July 27, 2026. PMID 42520497. https://doi.org/10.1016/j.ijgc.2026.104862 (subscription access)

Precancerous changes and the risk of recurrence remain central to preventing and managing vulvar cancer

Many vulvar cancers are preceded by precancerous changes, including VIN (vulvar intraepithelial neoplasia, precancerous cell changes in the surface layer of the vulva), and understanding which lesions recur or progress helps guide monitoring and treatment. Research this month looks at recurrence and at how precancerous and benign lesions are classified.

Additional citations on this topic:

  • de Vries DC, et al. "Recurrence in High-grade Vulvar Intraepithelial Neoplasia: A Comprehensive Cohort Analysis." Journal of Lower Genital Tract Disease. July 1, 2026. PMID 42138258. https://doi.org/10.1097/LGT.0000000000000960 (open access; license unverified)
  • Scolyer A, et al. "Vulvar Low-Grade Squamous Intraepithelial Lesion (LSIL) and Small Condyloma are Overlapping Clinicopathologic Entities." Journal of Lower Genital Tract Disease. July 1, 2026. PMID 42049006. https://doi.org/10.1097/LGT.0000000000000956 (open access; license unverified)
  • Sibarani CNR, et al. "Risk Factors for Recurrence in Vulvar Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis." Cancer Medicine. July 2026. PMID 42503484. https://doi.org/10.1002/cam4.72110 (restricted license, CC BY-NC-ND)

Life after treatment, including quality of life, information, and menopause care, is a legitimate and important part of vulvar cancer care

The physical and emotional effects of treatment, and the information people receive along the way, shape daily life long after active treatment ends. Research this month addresses survivorship and the support people need.

Additional citations on this topic:

  • DiSipio T, et al. "Vaginal and vulvar cancer patient experiences of the information pathway from pre-diagnosis to treatment." Supportive Care in Cancer. July 21, 2026. PMID 42481795. https://doi.org/10.1007/s00520-026-11022-0 (open access; license unverified)
  • da Silva-Filho AL, et al. "Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age." International Journal of Gynaecology and Obstetrics. July 22, 2026. PMID 42483786. https://doi.org/10.1002/ijgo.71188 (open access; license unverified)

Who gets timely care is not the same for everyone, and that gap is being measured

Delays in starting treatment and differences in outcomes across racial, ethnic, and socioeconomic groups are a real and potentially fixable part of vulvar cancer care. Research this month examines these disparities.

Additional citations on this topic:

  • Yousif A, et al. "Racial disparities in time to treatment initiation and survival outcomes in patients with vulvar cancer: a national cancer database analysis." International Journal of Clinical Oncology. July 6, 2026. PMID 42410146. https://doi.org/10.1007/s10147-026-03111-1 (open access; license unverified)

What Does This Mean for Me?

If you're being staged for advanced vulvar cancer, it's reasonable to ask your care team how imaging fits into your plan. A PET/CT scan may help clarify whether disease has spread when a cancer is more advanced, but it doesn't replace the surgical checking of your groin lymph nodes, and MRI may give a clearer picture of the tumor itself. A good question to ask is: "Which scans will you use to plan my treatment, and what will each one tell us?"

If you have a vulvar symptom that isn't going away, don't let it be brushed off. A persistent itch, a red or scaly patch, or a sore that doesn't heal, especially one that hasn't improved after creams or antifungal treatment, is worth a second look and sometimes a biopsy. Rare vulvar cancers are frequently mistaken for common skin conditions, and the delay that causes is one of the most avoidable problems in this disease. If a pigmented spot is new, changing, or worrying you, mention it specifically; most turn out to be benign, but the ones that aren't are best caught early. You can ask directly: "Should this be biopsied, or is there a reason we're watching it instead?"

If you're hearing about targeted therapies and molecular testing, know that this is an active research frontier rather than a set of established options for vulvar cancer. Research this month suggests the HER2 target is uncommon in vulvar squamous cell carcinoma, so it's not a solution for most people based on today's evidence, but the fact that scientists are systematically searching for such targets is encouraging for the future.

 

This digest is prepared by OCRA (Ovarian Cancer Research Alliance) for patients, caregivers, and advocates. It is intended to inform, not to guide individual treatment decisions. Please speak with your care team about what research findings may mean for your specific situation.

Sources

Directly Referenced in This Digest

  1. Gazawi R, et al. "PET Imaging in Vulvar Cancer: A Literature Review of the Current Evidence and Clinical Applications." Cancers (Basel). July 17, 2026. PMID 42512371. https://doi.org/10.3390/cancers18142308
  2. Karam F, et al. "Vulvar Extramammary Paget Disease: Diagnostic Challenge and Surgical Management in a Case Report." Healthcare (Basel). July 14, 2026. PMID 42512612. https://doi.org/10.3390/healthcare14142096
  3. De Giorgi V, et al. "Melanocytic nevi in the genital area: dermoscopic clues to diagnosis." Dermatology Reports. July 6, 2026. PMID 42405890. https://doi.org/10.4081/dr.2026.10927
  4. Farias Müller NL, et al. "HER2 Expression in Squamous Cell Carcinoma of the Vulva: A Systematic Review and Meta-Analysis." Cancers (Basel). July 6, 2026. PMID 42449705. https://doi.org/10.3390/cancers18132162

Additional Citations on Related Topics

These are on-topic papers published in July 2026 that are either not discussed in full above or are behind access restrictions; they are provided by citation so readers can locate them.

  1. Imperio-Onglao R, et al. "Sentinel Lymph Node Biopsy for Gynecologic Cancers." Obstetrical & Gynecological Survey. July 6, 2026. PMID 42406983. https://doi.org/10.1097/OGX.0000000000001553 (subscription access)
  2. Senda Y, et al. "A Rare Case of Extramammary Paget Disease With Concurrent Herpes Simplex Virus Infection: Three-Color Immunohistochemical Analysis for Re-Evaluating Previous Hypotheses." Pathology International. July 2026. PMID 42402155. https://doi.org/10.1111/pin.70146 (subscription access)
  3. Asher N, et al. "Vulvar and Vaginal Melanoma: Real-world Clinical Outcomes and Prognostic Differences From a Single-center Experience." Journal of Lower Genital Tract Disease. July 1, 2026. PMID 42044311. https://doi.org/10.1097/LGT.0000000000000959 (subscription access)
  4. Warmbold J, et al. "Inhibition of Plasminogen Activator Inhibitor-1 (PAI-1) by Tiplaxtinin Attenuates the Aggressive Phenotype of Vulvar Squamous Cell Carcinoma Cells." In Vivo. July–August 2026. PMID 42379802. https://doi.org/10.21873/invivo.14345 (subscription access)
  5. Kjölhede K, et al. "Treatment patterns and outcomes in perineal primary vulvar cancer—a population-based Swedish cohort study." Acta Obstetricia et Gynecologica Scandinavica. July 22, 2026. PMID 42483828. https://doi.org/10.1111/aogs.70315 (open access; license unverified)
  6. Ten Eikelder M, et al. "Clitoral reconstructive surgery for patients with vulvar carcinoma." Gynecologic Oncology. July 21, 2026. PMID 42480492. https://doi.org/10.1016/j.ygyno.2026.07.013 (subscription access)
  7. Haidopoulos D, et al. "European Society of Gynaecological Oncology Consensus Statement on the prevention of surgical complications in gynecologic oncology." International Journal of Gynecological Cancer. July 27, 2026. PMID 42520497. https://doi.org/10.1016/j.ijgc.2026.104862 (subscription access)
  8. de Vries DC, et al. "Recurrence in High-grade Vulvar Intraepithelial Neoplasia: A Comprehensive Cohort Analysis." Journal of Lower Genital Tract Disease. July 1, 2026. PMID 42138258. https://doi.org/10.1097/LGT.0000000000000960 (open access; license unverified)
  9. Scolyer A, et al. "Vulvar Low-Grade Squamous Intraepithelial Lesion (LSIL) and Small Condyloma are Overlapping Clinicopathologic Entities." Journal of Lower Genital Tract Disease. July 1, 2026. PMID 42049006. https://doi.org/10.1097/LGT.0000000000000956 (open access; license unverified)
  10. Sibarani CNR, et al. "Risk Factors for Recurrence in Vulvar Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis." Cancer Medicine. July 2026. PMID 42503484. https://doi.org/10.1002/cam4.72110 (restricted license, CC BY-NC-ND)
  11. DiSipio T, et al. "Vaginal and vulvar cancer patient experiences of the information pathway from pre-diagnosis to treatment." Supportive Care in Cancer. July 21, 2026. PMID 42481795. https://doi.org/10.1007/s00520-026-11022-0 (open access; license unverified)
  12. da Silva-Filho AL, et al. "Menopausal hormone therapy and comprehensive postmenopausal care in gynecologic cancer survivors: A position paper from the FIGO Committee on Women at Menopausal Age." International Journal of Gynaecology and Obstetrics. July 22, 2026. PMID 42483786. https://doi.org/10.1002/ijgo.71188 (open access; license unverified)
  13. Yousif A, et al. "Racial disparities in time to treatment initiation and survival outcomes in patients with vulvar cancer: a national cancer database analysis." International Journal of Clinical Oncology. July 6, 2026. PMID 42410146. https://doi.org/10.1007/s10147-026-03111-1 (open access; license unverified)

A note on how this digest was made: This edition was built by searching PubMed for papers published in July 2026, using targeted searches across the vulvar cancer landscape (sentinel lymph node and groin management, surgery and morbidity, radiation/chemoradiation, lichen sclerosus and VIN/dVIN/HSIL, HPV prevention, rare subtypes, immunotherapy and targeted therapy, biomarkers, survivorship, and disparities) plus a dedicated qualitative search. Papers summarized in full are open-access under a permitted license (CC0, CC BY, CC BY-SA, CC BY-ND, or CC BY-NC); on-topic papers under other licenses, or whose license could not be confirmed, are listed by citation only. A companion methodology report, available separately, documents the full search-and-screening process and every paper reviewed.

 

0 comments

Comments